Quick Answer
LIGAND PHARMACEUTICALS INC reported Operating Income of $41.00 million for fiscal year 2025.
LIGAND PHARMACEUTICALS INC Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | $41.00M | +281.4% |
| 2024 | -$22.61M | -289.3% |
| 2023 | $11.94M | +293.2% |
| 2022 | $3.04M | -97.1% |
| 2021 | $103.85M | +176.9% |
| 2020 | $37.50M | -95.4% |
| 2019 | $807.08M | +392.9% |
| 2018 | $163.73M | +140.5% |
| 2017 | $68.08M | +55.1% |
| 2016 | $43.88M | +60.6% |
| 2015 | $27.33M | +39.2% |
| 2014 | $19.63M | +31.3% |
| 2013 | $14.94M | +7642.5% |
| 2012 | $193.0K | +122.0% |
| 2011 | -$878.0K | +97.0% |
| 2010 | -$29.30M | -194.0% |
| 2009 | -$9.97M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $54.93M | +1647.7% | +550.5% |
| June 30, 2025 | $8.44M | +144.2% | +123.3% |
| March 31, 2025 | -$36.22M | -1312.0% | -1252.3% |
| September 30, 2024 | $3.14M | +2.1% | +116.5% |
| June 30, 2024 | -$19.10M | -863.2% | -739.2% |
| March 31, 2024 | $2.99M | -79.0% | -2.9% |
| September 30, 2023 | $3.08M | -75.1% | +255.2% |
| June 30, 2023 | -$1.98M | -122.9% | -114.0% |
- LIGAND PHARMACEUTICALS INC showed an increase of +281.4% in Operating Income compared to the prior fiscal year.
- Over the 2009–2025 period, LIGAND PHARMACEUTICALS INC’s operating income has grown by 511.4% (from -$9.97 million to $41.00 million).
- The most recent figure is from LIGAND PHARMACEUTICALS INC’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 27, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: